Steadybase.

Nasus Pharma Ltd.

Website Investor relations
  • NSRX · NYSE
  • Pharmaceutical Preparations
  • Tel Aviv - Yafo, L3
  • CIK 0002029039

Updated from SEC filings through

Top things to know

Executives

Nasus Pharma Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Tel Aviv - Yafo, L3. It trades as NSRX on NYSE. Revenue was $1.2B in the fiscal year ending December 31, 2025. Brendan P. O'Grady is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023
Revenue $1.2B
20-F, 2026-03-25
Not on file Not on file
Operating income -$4.9M
20-F, 2026-03-25
-$1.1M
20-F, 2026-03-25
-$1.1M
20-F, 2026-03-25
SG&A $2.7M
20-F, 2026-03-25
$743K
20-F, 2026-03-25
$580K
20-F, 2026-03-25
Net income -$5.9M
20-F, 2026-03-25
-$1.5M
20-F, 2026-03-25
-$1.1M
20-F, 2026-03-25

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Brendan P. O'Grady Chief Executive Officer Form 3, July 31, 2026
Dan Benjamin Teleman Chief Executive Officer Form 4, July 29, 2026
Nir Sassi Chief Financial Officer Form 3, November 19, 2026
Oren Elmaliah Interim CFO Form 3, September 23, 2026
Eyal Rubin
Global CFO | Strategic Finance, M&A & Capital Markets | Driving Growth, Governance & Operational Excellence | Pharma · Biotech · Tech
Chief Financial Officer Form 4, September 21, 2026
Dalia Megiddo Chief Development Officer Form 3, March 27, 2026

What Nasus Pharma Ltd does

Nasus Pharma develops powder-based intranasal therapies using Nasax® technology for rapid drug delivery, improved absorption, and emergency treatments.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 9.0 million (as of December 31, 2025) 20-F, March 25, 2026
Auditor Brightman Almagor Zohar & Co (Tel -Aviv, Israel) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
June 17, 2026 Dan Benjamin Teleman
Chief Executive Officer
Buy 6,550 $20K Form 4, June 22, 2026
April 22, 2026 Dan Benjamin Teleman
Chief Executive Officer
Buy 2,900 $11K Form 4, April 22, 2026
March 31, 2026 Dan Benjamin Teleman
Chief Executive Officer
Buy 15,000 $31K Form 4, April 1, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Nasus Pharma Ltd

What does Nasus Pharma Ltd do?
In its own words, from Item 1 of its 10-K: "Nasus Pharma develops powder-based intranasal therapies using Nasax® technology for rapid drug delivery, improved absorption, and emergency treatments."
What is Nasus Pharma Ltd's revenue?
$1.2B for the fiscal year ending December 31, 2025, from its 20-F filed March 25, 2026.
Is Nasus Pharma Ltd profitable?
Nasus Pharma Ltd reported net income of -$5.9M for the fiscal year ending December 31, 2025.
Who is the CEO of Nasus Pharma Ltd?
Brendan P. O'Grady, Chief Executive Officer, as named in a 3 filed July 31, 2026.
Who is the CFO of Nasus Pharma Ltd?
Nir Sassi, Chief Financial Officer, as named in a 3 filed November 19, 2026.
Where is Nasus Pharma Ltd headquartered?
Tel Aviv - Yafo, L3.
What is Nasus Pharma Ltd's stock ticker?
NSRX on NYSE.
What industry is Nasus Pharma Ltd in?
Pharmaceutical Preparations, SIC code 2834.
What is Nasus Pharma Ltd's website?
nasuspharma.com. Investor relations: https://ir.nasuspharma.com/.
Is Nasus Pharma Ltd a public company?
Yes. Nasus Pharma Ltd files with the SEC under CIK 0002029039 and trades as NSRX.
Who audits Nasus Pharma Ltd?
Brightman Almagor Zohar & Co, Tel -Aviv, Israel, as named in its latest annual report (10-K).
How many shares of Nasus Pharma Ltd are outstanding?
9.0 million shares as of December 31, 2025, from its 20-F filed March 25, 2026.
Have Nasus Pharma Ltd insiders traded stock recently?
Since March 31, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $62K on Forms 4 and 5. The most recent: Dan Benjamin Teleman (Chief Executive Officer) bought 6,550 shares on June 17, 2026.